Gene therapy for hemophilia B allowed almost three-fourths of patients to discontinue prophylactic factor IX therapy with no increase in bleeding, results of the pivotal BENEGENE-2 trial showed. The ...
Allison Wheeler, MD, delves into the complexities of prophylaxis for mild to moderate hemophilia A cases, exploring a patient-centric approach, situational prophylaxis during high-risk activities, and ...
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) for its anti-tissue ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved fidanacogene elaparvovec-dzkt for treatment of adults with moderate to severe hemophilia B. The ...
Please provide your email address to receive an email when new articles are posted on . Once-monthly fitusiran prophylaxis improved outcomes compared with on-demand treatment for patients with severe ...
After quite the regulatory process, with Roctavian (valoctocogene roxaparvovec) BioMarin has a potential blockbuster. On June 29th, Roctavian became the first gene therapy approved in the U.S. in the ...
Prophylactic treatment with trimethoprim-sulfamethoxazole (TMP-SMX) significantly reduced the risk for serious infections by approximately 50% in patients with antineutrophil cytoplasmic antibody ...
ORLANDO, Florida ― The aggressive chemotherapy regimen given to children with acute lymphocytic leukemia (ALL) during the induction phase, which aims to push the disease into remission, also depletes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results